Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics

摘要: From bronchoprovocation studies and investigations of the acute effects drugs that inhibit leukotrienes (LT), hypothesis has emerged are important mediators airway obstruction other symptoms in aspirin-intolerant asthma (AIA). However, it yet not been shown if subjects with AIA respond favorably to clinical treatment leukotriene inhibitors. Therefore, a double-blind placebo-controlled crossover study, we examined 6 wk leukotriene-pathway inhibitor zileuton (600 mg, four times daily) 40 patients well-characterized AIA. The was added existing therapy, which included medium high doses inhaled (average daily dose 1,030 μ g beclomethasone or budesonide) oral glucocorticosteroids (4 25 mg/d) for all but one patients. On top this treated baseline, there were no significant adding placebo, indicating their kept relatively stable. an ...